{
    "clinical_study": {
        "@rank": "70554", 
        "arm_group": {
            "arm_group_label": "Treatment group", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety, efficacy and pharmacokinetics of gabapentin enacarbil in moderate to\n      severe primary RLS patients with moderate renal impairment and to confirm dosage and\n      administration in such population."
        }, 
        "brief_title": "Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Restless Legs Syndrome (RLS)", 
        "condition_browse": {
            "mesh_term": [
                "Renal Insufficiency", 
                "Restless Legs Syndrome", 
                "Psychomotor Agitation"
            ]
        }, 
        "detailed_description": {
            "textblock": "This study is a multicenter, non-blinded, non-comparative study.  Patients who meet the\n      eligible criteria will undergo one week observation period followed by four week treatment\n      period.  In treatment period, patients will receive gabapentin enacarbil orally one daily\n      after dinner.  After the four-week treatment period with gabapentin enacarbil, a one-week\n      post-observation period will be undertaken."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who have been diagnosed with restless legs syndrome (RLS) according to the\n             international RLS Study Group Diagnostic Criteria\n\n          -  Patients whose score is 15 or greater on the International RLS (IRLS) Rating Scale on\n             the first day of the pre-observation period.\n\n          -  Patients whose creatinine clearance level at the first day of pre-observation period\n             is \u226530 mL/min to <60mL/min estimated by Cockcroft-Gaul t equation\n\n          -  Patients who provide written consent\n\n        Exclusion Criteria:\n\n          -  Patients with sleep disorder such as sleep apnea syndrome,  which affects the RLS\n             evaluation\n\n          -  Patients with history of augmentation and treatment rebound of RLS symptoms when\n             using dopamine agonis\n\n          -  Patients with neuropathy and movement disorder (diabetic neuropathy, Parkinson's\n             disease, multiple sclerosis, dyskinesia, rheumatoid arthritis etc)\n\n          -  Patients with uncontrolled diabetes [HbA1c>7.5% (NGSP value), in the past six\n             months], iron deficiency anemia, or drug administration of hypnotic sedatives.\n\n          -  Patients who attempted suicide within six months prior to the consent obtained, or\n             who have been diagnosed as a suicide risk by investigator or sub-investigator\n\n          -  Patients with moderate or severe depression\n\n          -  Patients with alcohol dependence or drug intoxication or who have a history of abuse\n             or drug dependence in the past one year\n\n          -  Patients whose job is shift work, professional driver, or engaging in hazardous\n             activities such as operating machinery\n\n          -  Patients with history of hypersensitivity to gabapentin\n\n          -  Patients who have experience to participate in other post-marketing clinical studies\n             or clinical trials within 12 weeks prior to the start of pre-observation\n\n          -  Others: patients who are concluded to be ineligible by an investigator or\n             sub-investigator as ineligible"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01981941", 
            "org_study_id": "8825-CL-0103"
        }, 
        "intervention": {
            "arm_group_label": "Treatment group", 
            "description": "Oral", 
            "intervention_name": "Gabapentin enacarbil", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Gabapentin", 
                "Gamma-Aminobutyric Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Gabapentin", 
            "Restless legs syndrome (RLS)"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chubu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chugoku", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansai", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanto", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyushu", 
                        "country": "Japan"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "Post-marketing Clinical Study of Gabapentin Enacarbil \u2015Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment\u2015", 
        "overall_contact": {
            "email": "clintrialtrials_info@jp.astellas.com", 
            "last_name": "Clinical Development Administration Dept."
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma Inc", 
            "last_name": "Medical Director", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in International Restless Leg Syndrome (IRLS) rating scale score", 
            "safety_issue": "No", 
            "time_frame": "Baseline and at 4 week of the treatment (or at discontinuation)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01981941"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in Investigator-rated clinical global impression (ICGI) score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and at 4 week of the treatment (or at discontinuation)"
            }, 
            {
                "description": "Baseline and at 4 week of the treatment (or at discontinuation)", 
                "measure": "Change in Patient-related clinical global impression (PCGI) score", 
                "safety_issue": "No", 
                "time_frame": "Baseline and at 4 week of the treatment (or at discontinuation)"
            }, 
            {
                "measure": "Safety assessed by the incidence of adverse events, vital signs, labo-tests, body weight and Epworth sleepiness scale", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 weeks"
            }, 
            {
                "measure": "Plasma gabapentin concentration", 
                "safety_issue": "No", 
                "time_frame": "Up to 5 weeks"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}